Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21541108 | 0.94 | TDP1 (0.44) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL21602829 | 0.91 | KMT2A (0.46) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL21902490 | 0.91 | MEN1 (0.47) | TDP1ATMMEN1KMT2AHDAC1 | |
| SCHEMBL21602828 | 0.90 | FOLH1 (0.47) | TDP1MEN1KMT2AHDAC1HDAC8 | |
| SCHEMBL15498944 | 0.88 | CAPN1 (0.44) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL31467206 | 0.88 | TDP1 (0.51) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL17381377 | 0.88 | FOLH1 (0.46) | MEN1KMT2AHDAC1HDAC8GAA | |
| SCHEMBL31384226 | 0.87 | NOD1 (0.41) | KMT2AFOLH1 | |
| SCHEMBL21664570 | 0.86 | TDP1 (0.49) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL22077841 | 0.85 | SIRT2 (0.48) | TDP1ATMMAPTNPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2024-02-29 | — | — | US | disclosed |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| US-11066667-B2 | Organic compositions to treat APOC3-related diseases | Arrowhead Pharmaceuticals, Inc. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210000964-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-01-07 | — | — | US | disclosed |
| EP-3736334-A1 | RNAI COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | Arrowhead Pharmaceuticals, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10786576-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| US-20190233817-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-08-01 | — | — | US | disclosed |
| US-10240153-B2 | Organic compositions to treat APOC3-related diseases | Arrowhead Pharmaceuticals, Inc. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170137814-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2017-05-18 | — | — | US | disclosed |
| WO-2016011123-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | ARROWHEAD RESEARCH CORPORATION (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2015200078-A1 | FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | TDP1 4722/4885ATM 1725/4885MAPT 4692/4885 |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | FABP1, FABP2, FABP3 | TDP1 4753/4885ATM 1810/4885MAPT 4642/4885 |
| US-10786576-B2 | Fatty acids and their use in conjugation to biomolecules | FABP1, FABP2, FABP3 | TDP1 4753/4885ATM 1810/4885MAPT 4642/4885 |
| US-20170137814-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | APOL1, APOB, LDLR | TDP1 1459/4885ATM 1595/4885MAPT 1751/4885 |
| US-20190233817-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | APOL1, APOB, LDLR | TDP1 1459/4885ATM 1595/4885MAPT 1751/4885 |
| US-10240153-B2 | Organic compositions to treat APOC3-related diseases | APOL1, APOB, LDLR | TDP1 1459/4885ATM 1595/4885MAPT 1751/4885 |
| US-20210000964-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | TDP1 4722/4885ATM 1725/4885MAPT 4692/4885 |
| US-11066667-B2 | Organic compositions to treat APOC3-related diseases | APOL1, APOB, LDLR | TDP1 1459/4885ATM 1595/4885MAPT 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.